Clicky

Xvivo Perfusion AB(XVIVO)

Description: Xvivo Perfusion AB (publ), a medical technology company, develops solutions for organ, tissue, and cell preservation and perfusion in connection with transplantation in Sweden, the United States, North America and South America, Europe, the Middle East, Africa, and the Asia Pacific. The company offers XVIVO System (XPS), an integrated off-the-shelf cardiac bypass system that includes various components needed to safely run normothermic ex vivo lung perfusion (EVLP); XPS Disposable Lung Kit that contains disposables and pre-packed products to suit requirement for sterility; and STEEN Solution, a buffered extracellular solution optimally designed to perfuse the isolated donor lung during EVLP. It also provides Perfadex Plus, an extracellular, low potassium, dextran-based electrolyte preservation solution; XVIVO Silicone Tubing Set for rapid flushing of donor lungs during procurement; and XVIVO LS and XVIVO Disposable Lung Set, a device for EVLP. In addition, the company offers XVIVO Organ Chamber, a single-use sterile disposable container intended to be used as a temporary receptacle for isolated lungs in preparation for eventual transplantation into a recipient; and XVIVO Lung Cannula Set, a single-use, sterile disposable product. The company was incorporated in 1998 and is headquartered in Gothenburg, Sweden.


Keywords: Medical Technology Transplantation Bypass Organ Transplantation Sterility Buffered Extracellular Solution Dextran Based Electrolyte Preservation Solution Rapid Flushing Sterile Disposable Product Xvivo Scientific Animation

Home Page: www.xvivoperfusion.com

MAessans gata 10
Gothenburg, 412 51
Sweden
Phone: 46 3 17 88 21 50


Officers

Name Title
Mr. Christoffer Rosenblad Chief Exec. Officer
Mr. Kristoffer Nordstrom CFO & Investor Relations
Ms. Lena Hagman B.Sc. Chief Operating Officer
Dr. Magnus Nilsson Ph.D. Sr. Advisor
Ms. Katrin Gisselfalt Ph.D. Global Quality Assurance & Regulatory Affairs Director
Mr. Andreas Wallinder M.D., Ph.D. Chief Medical Officer
Mr. Johan Holmstrom Chief Commercial Officer
Ms. Charlotte Walldal Global R&D director
Jaya Tiwari VP Clinical and Regulatory Affairs
Mr. Christer de Flon Mang.

Exchange: ST

Country: SE

Currency: Swedish krone (kr)

Forward PE: 86.2069
Trailing PE: 207.9208
Price-to-Book MRQ: 4.232
Price-to-Sales TTM: 16.5849
IPO Date:
Fiscal Year End: December
Full Time Employees: 118
Back to stocks